Finance

Lists
Outlook: 76.5% bullish·0.0% bearish
Go to analysis
MCK:NYSE
McKesson Corp
$1,079.79
-0.54%
(-5.83) 1D
$1,079.79
0.00% (0.00)
After hours
Closed: Nov 11, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCK...
Open
$1,075.23
High
$1,081.47
Low
$1,067.38
Mkt. cap
124.67B
Avg. vol.
742.12K
Volume
474.89K
Dividend
0.35%
Quarterly dividend
$0.94
Ex-dividend date
Sep 1, 2026
P/E ratio
27.79
52-wk high
$1,121.50
52-wk low
$723.68
EPS
$38.86
Beta
0.27
Shares outstanding
115.46M
No. of employees
42K
Open
$1,075.23
High
$1,081.47
Low
$1,067.38
Mkt. cap
124.67B
Avg. vol.
742.12K
Volume
474.89K
Dividend
0.35%
Quarterly dividend
$0.94
Ex-dividend date
Sep 1, 2026
P/E ratio
27.79
52-wk high
$1,121.50
52-wk low
$723.68
EPS
$38.86
Beta
0.27
Shares outstanding
115.46M
No. of employees
42K
News stories
From web sources and news partners
Profile
McKesson Corporation is an American publicly traded company that distributes pharmaceuticals and provides health information technology, medical supplies, and health management tools. The company delivers a third of all pharmaceutical products used or consumed in North America and employs over 80,000 employees. With $308.9 billion in 2024 revenue, it is the ninth-largest company by revenue in the United States and the nation's largest health care company. The company is headquartered in Irving, Texas. It is a component of the S&P 500 and is listed on the New York Stock Exchange, where it is traded under the ticker symbol "MCK". McKesson provides extensive network of infrastructure for the healthcare industry and was an early adopter of technologies, including barcode scanning for distribution, pharmacy robotics, and RFID tags. The company has been named in a federal lawsuit for profiting from the opioid epidemic in the United States. Throughout the COVID-19 pandemic, McKesson was a key vaccine distributor, serving as the US government's centralized distributor for hundreds of millions of COVID-19 vaccine doses and ancillary supply kits for over a billion doses. Wikipedia
About McKesson Corp
CEOBrian S. Tyler
Employees42.3K
Founded1835
Headquarters-
SectorHealth Care
IndustryHealth care provider
Websitemckesson.com
Analyst ratings
Based on 13 analysts giving stock ratings to MCK in the past 3 months
Strong buy
Buy
11
Hold
2
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for MCK in the last 3 months.
Highest
Current $1,079.79
$1,260.00 (+16.69%)
Average
$1,147.33 (+6.25%)
Lowest
$913.00 (-15.45%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allen Lutz
Bank of America Securities
Buy
Maintained
$1,250.00
+15.8%
11/10/2026
Lisa Gill
J.P. Morgan
Buy
Maintained
$1,255.00
+16.2%
11/10/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
$1,050.00
-2.8%
11/05/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$1,200.00
+11.1%
11/05/2026
Kevin Caliendo
UBS
Buy
Reiterated
$1,250.00
+15.8%
11/05/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$1,200.00
+11.1%
11/05/2026
Erin Wright
Morgan Stanley
Buy
Reiterated
$1,260.00
+16.7%
11/05/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$1,200.00
+11.1%
11/05/2026
Ryan Halsted
RBC Capital
Hold
Reiterated
$965.00
-10.6%
11/04/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$1,225.00
+13.4%
11/05/2026
Glen Santangelo
Barclays
Buy
Maintained
$1,000.00
-7.4%
11/05/2026
George Hill
Deutsche Bank
Buy
Maintained
$913.00
-15.4%
10/06/2026
Ryan Daniels
William Blair
Buy
Maintained
-
-
10/05/2026
Stephen Baxter
Wells Fargo
Hold
Reiterated
$933.00
-13.6%
08/11/2026
Daniel Grosslight
Citi
Buy
Reiterated
$1,000.00
-7.4%
08/10/2026
Max Smock
William Blair
Buy
Reiterated
-
-
05/08/2026
Last report
Nov 4, 2026
Fiscal period
Q2 2027
$11.68 / $10.75
+8.62%beat
Revenue / Est. (USD)
110.96B / 109.95B
+0.91%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
106.16B
96.30B
105.38B
110.96B
Cost of goods sold
102.49B
92.25B
101.70B
107.05B
Cost of revenue
102.49B
92.25B
101.70B
107.05B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.03B
1.92B
2.26B
2.27B
Operating expense
2.03B
1.92B
2.26B
2.27B
Total operating expenses
104.52B
94.17B
103.96B
109.32B
Operating income
1.64B
2.13B
1.42B
1.64B
Other non operating income
74.00M
-156.00M
66.00M
63.00M
EBT including unusual items
1.63B
2.12B
1.31B
1.56B
EBT excluding unusual items
1.65B
2.10B
1.41B
1.60B
Income tax expense
380.00M
270.00M
276.00M
266.00M
Effective tax rate
23.31%
12.71%
21.10%
17.03%
Other operating expenses
-
-
-
-
Net income
1.19B
1.68B
614.00M
1.22B
Net profit margin
1.12%
1.75%
0.58%
1.10%
Earnings per share
9.34
11.69
9.93
11.68
Interest and investment income
-
179.00M
-
-
Interest expense
-63.00M
-61.00M
-77.00M
-105.00M
Net interest expenses
-63.00M
118.00M
-77.00M
-105.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.83B
2.19B
1.62B
1.83B
Gain or loss from assets sale
-
-488.00M
-6.00M
-18.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps